Testing new drug combos for advanced mucosal melanoma
Part of Cancer, Skin clinical trials.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with metastatic mucosal melanoma (melanoma starting in moist body linings that has spread)
- Your cancer is measurable on scans (like CT or MRI)
- You are in generally good health with normal organ function (kidneys, liver, heart, blood counts)
- You have not had prior treatment with immune checkpoint inhibitors (like nivolumab or pembrolizumab) or axitinib
- Cancer has not spread to your brain or spinal cord
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, HX009 and IN10018, with or without standard chemotherapy, for people with advanced solid tumors that haven't responded to treatment or have no standard options. It aims to see if this combination can help shrink or control the cancer.
This trial tests whether two medications, lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy), given before and after surgery, can help reduce the chance of mucosal melanoma coming back. If you are eligible, you would receive these drugs in addition to your standard surgery.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
This trial tests a combination of two drugs (carilizumab and apatinib) plus radiation therapy for people with advanced mucosal melanoma that has come back or spread. The goal is to see if this treatment can help control the cancer.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This trial tests a combination of two drugs (SHR-1701 and famitinib) before surgery to shrink mucosal melanoma, followed by additional treatment based on how the tumor responds. It aims to improve outcomes for patients with this rare type of melanoma.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.